Department of Bacteriology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Antimicrob Agents Chemother. 2011 Sep;55(9):4188-95. doi: 10.1128/AAC.00398-11. Epub 2011 Jul 11.
The clinical vancomycin-intermediate Staphylococcus aureus (VISA) strain Mu50 carries two mutations in the vraSR and graRS two-component regulatory systems (TCRSs), namely, vraS(I5N) and graR(N197S) (hereinafter designated graR). The clinical heterogeneously vancomycin-intermediate S. aureus (hVISA) strain Mu3 shares with Mu50 the mutation in vraS that encodes the VraS two-component histidine kinase. Previously, we showed that introduction of the plasmid pgraR, carrying the mutated two-component response regulator graR, converted the hVISA strain Mu3 into VISA (vancomycin MIC = 4 mg/liter). Subsequently, however, we found that the introduction of a single copy of graR into the Mu3 chromosome by a gene replacement method did not confer on Mu3 the VISA phenotype. The gene-replaced strain Mu3graR thus obtained remained hVISA (MIC ≤ 2 mg/liter), although a small increase in vancomycin MIC was observed compared to that of the parent strain Mu3. Reevaluation of the Mu3 and Mu50 genomes revealed the presence of another mutation responsible for the expression of the VISA phenotype in Mu50. Here, we demonstrate that in addition to the two regulator mutations, a third mutation found in the Mu50 rpoB gene, encoding the RNA polymerase β subunit, was required for Mu3 to achieve the level of vancomycin resistance of Mu50. The selection of strain Mu3graR with rifampin gave rise to rpoB mutants with various levels of increased vancomycin resistance. Furthermore, 3 (33%) of 10 independently isolated VISA strains established from the heterogeneous subpopulations of Mu3graR were found to possess rpoB mutations with or without an accompanying rifampin-resistance phenotype. The data indicate that a sizable proportion of the resistant hVISA cell subpopulations is composed of spontaneous rpoB mutants with various degrees of increased vancomycin resistance.
临床万古霉素中介金黄色葡萄球菌(VISA)菌株 Mu50 携带 vraSR 和 graRS 双组分调节系统(TCRS)中的两个突变,即 vraS(I5N)和 graR(N197S)(以下称为 graR)。临床异质性万古霉素中介金黄色葡萄球菌(hVISA)菌株 Mu3 与 Mu50 共享编码 VraS 双组分组氨酸激酶的 vraS 突变。先前,我们表明,引入携带突变的双组分应答调节子 graR 的质粒 pgraR,将 hVISA 菌株 Mu3 转化为 VISA(万古霉素 MIC = 4 毫克/升)。然而,随后我们发现,通过基因替换方法将单个拷贝的 graR 引入 Mu3 染色体中,并未使 Mu3 获得 VISA 表型。因此,获得的基因替换菌株 Mu3graR 仍然是 hVISA(MIC ≤ 2 毫克/升),尽管与亲本菌株 Mu3 相比,万古霉素 MIC 略有增加。对 Mu3 和 Mu50 基因组的重新评估表明,存在另一个突变,该突变负责 Mu50 中 VISA 表型的表达。在这里,我们证明,除了两个调节子突变外,Mu50 的 rpoB 基因中发现的第三个突变,编码 RNA 聚合酶β亚基,也是 Mu3 达到 Mu50 水平的万古霉素抗性所必需的。用利福平选择 Mu3graR 菌株导致 rpoB 突变体具有不同水平的万古霉素抗性增加。此外,从 Mu3graR 的异质亚群中分离出的 10 个独立的 VISA 菌株中有 3 个(33%)被发现具有 rpoB 突变,这些突变要么带有伴随的利福平耐药表型,要么没有。这些数据表明,相当一部分耐药 hVISA 细胞亚群由具有不同程度增加的万古霉素抗性的自发 rpoB 突变体组成。